These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38468289)

  • 21. Bispecific Antibodies Enable Synthetic Agonistic Receptor-Transduced T Cells for Tumor Immunotherapy.
    Karches CH; Benmebarek MR; Schmidbauer ML; Kurzay M; Klaus R; Geiger M; Rataj F; Cadilha BL; Lesch S; Heise C; Murr R; Vom Berg J; Jastroch M; Lamp D; Ding J; Duewell P; Niederfellner G; Sustmann C; Endres S; Klein C; Kobold S
    Clin Cancer Res; 2019 Oct; 25(19):5890-5900. PubMed ID: 31285373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific antibodies in cancer immunotherapy.
    Chen S; Li J; Li Q; Wang Z
    Hum Vaccin Immunother; 2016 Oct; 12(10):2491-2500. PubMed ID: 27249163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment.
    Qiu Y; Liao P; Wang H; Chen J; Hu Y; Hu R; Zhang H; Li Z; Cao M; Yang Y; Li M; Xie X; Li Y
    Int J Biol Sci; 2023; 19(15):4948-4966. PubMed ID: 37781520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy with bispecific antibodies.
    Thielemans KM
    Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody and antibody fragments for cancer immunotherapy.
    Chen W; Yuan Y; Jiang X
    J Control Release; 2020 Dec; 328():395-406. PubMed ID: 32853733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of an artificial antibody specific for HLA/peptide complex derived from cancer stem-like cell/cancer-initiating cell antigen DNAJB8.
    Tadano H; Tsukahara T; Mizushima E; Akamatsu A; Watanabe K; Nojima I; Kubo T; Kanaseki T; Hirohashi Y; Sato N; Torigoe T
    Br J Cancer; 2020 Oct; 123(9):1387-1394. PubMed ID: 32753678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy.
    Xie F; Zhang L; Shi S; Zheng A; Di J; Jin S; Miao X; Wu F; Chen X; Zhang Y; Wei X; Xu Y
    MAbs; 2022; 14(1):2115205. PubMed ID: 36041060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy.
    Kujawski M; Li L; Bhattacharya S; Wong P; Lee WH; Williams L; Li H; Chea J; Poku K; Bowles N; Vaidehi N; Yazaki P; Shively JE
    BMC Cancer; 2019 Sep; 19(1):882. PubMed ID: 31488104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab® bispecific antibody against solid tumors.
    Xu G; Qian N; Liu Y; Li H; Yang C; Wang J; Wang F; Chen L; Bai G; Xu Q; Pan X; Gao X
    Immunobiology; 2022 Nov; 227(6):152283. PubMed ID: 36198215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies.
    Carrara SC; Bogen JP; Fiebig D; Grzeschik J; Hock B; Kolmar H
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
    Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
    Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
    Stieglmaier J; Benjamin J; Nagorsen D
    Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.
    Zou J; Chen D; Zong Y; Ye S; Tang J; Meng H; An G; Zhang X; Yang L
    Cancer Sci; 2015 May; 106(5):512-21. PubMed ID: 25664501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.
    Ma Z; Zhou Z; Duan W; Yao G; Sheng S; Zong S; Zhang X; Li C; Liu Y; Ou F; Dahar MR; Huang Y; Yu L
    Cancer Immunol Immunother; 2024 Mar; 73(5):82. PubMed ID: 38554200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selection and expression of CD40 single chain variable fragment by phage display and evaluation of tumor specific immune activation.
    Lu L; Wang X; Zhang A; Huang F; Yan Y; Li W; Fu W
    Int Immunopharmacol; 2019 Jun; 71():224-232. PubMed ID: 30925323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
    Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
    J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.